Is lipopolysaccharide-binding protein a useful marker for systemic infection on the ICU?

2001 ◽  
Vol 18 (Supplement 21) ◽  
pp. 119-120
Author(s):  
A. Nierhaus ◽  
B. Montag ◽  
D. Frings ◽  
N. Suerhoff ◽  
J. Schulte am Esch
Keyword(s):  
Binding Protein ◽  
Protein A ◽  
Systemic Infection ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

scholarly journals Lipopolysaccharide-Binding Protein: A New Biomarker for Infectious Endocarditis?

2009 ◽  
Vol 55 (2) ◽  
pp. 295-304 ◽  
Author(s):  
Tanja Vollmer ◽  
Cornelia Piper ◽  
Knut Kleesiek ◽  
Jens Dreier
Keyword(s):  
Binding Protein ◽  
Molecular Genetic ◽  
Protein A ◽  
Response To Therapy ◽  
Infectious Endocarditis ◽  
Therapeutic Monitoring ◽  
Lipopolysaccharide Binding Protein ◽  
Reactive Protein ◽  
Wbc Count ◽  
Lipopolysaccharide Binding

Abstract Background: Infectious endocarditis (IE) is a bacterial infection of the endocardium. Diagnosis is based on results obtained from echocardiography, blood cultures, and molecular genetic screening for bacteria and on data for inflammatory markers such as the leukocyte (WBC) count and the C-reactive protein (CRP) concentration. The aim of the present study was to evaluate lipopolysaccharide-binding protein (LBP) as a supportive biomarker for the diagnosis and therapeutic monitoring of IE. Methods: We measured LBP and CRP concentrations and WBC counts in 57 IE patients at hospital admission, 40 patients with noninfectious heart valve diseases (HVDs), and 55 healthy blood donors. The progression of these 3 markers and the influence of cardiac surgery on them were evaluated in 29 IE patients and 21 control patients. Results: Serum LBP concentrations were significantly higher in IE patients [mean (SD), 33.41 (32.10) mg/L] compared with HVD patients [6.67 (1.82) mg/L, P < 0.0001] and healthy control individuals [5.61 (1.20) mg/L]. The progression in the LBP concentration during therapy of IE patients correlated with the changes in the CRP concentration. The 2 markers were equally influenced by antibiotic treatment and surgical intervention. Conclusions: Serial LBP measurement may provide an effective and useful tool for evaluating the response to therapy in IE patients. We found a strong correlation between LBP and CRP concentrations; LBP has a tendency to increase earlier in cases of reinfection.

Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule

2011 ◽  
Vol 39 (4) ◽  
pp. 989-993 ◽  
Author(s):  
Ralf R. Schumann
Keyword(s):  
Binding Protein ◽  
Protein A ◽  
Lipopolysaccharide Binding Protein ◽  
New Findings ◽  
Substantial Progress ◽  
Large Protein Family ◽  
Functional Consequences ◽  
Health And Disease ◽  
Lipopolysaccharide Binding ◽  
Key Questions

LBP [LPS (lipopolysaccharide)-binding protein] was discovered approximately 25 years ago. Since then, substantial progress has been made towards our understanding of its function in health and disease. Furthermore, the discovery of a large protein family sharing functional and structural attributes has helped in our knowledge. Still, key questions are unresolved, and here an overview on the old and new findings on LBP is given. LBP is an acute-phase protein of the liver, but is also synthesized in other cells of the organism. While LBP is named after the ability to bind to LPS of Gram-negative bacteria, it also can recognize other bacterial compounds, such as lipopeptides. It has been shown that LBP is needed to combat infections; however, the main mechanism of action is still not clear. New findings on natural genetic variations of LBP leading to functional consequences may help in further elucidating the mechanism of LBP and its role in innate immunity and disease.

Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients

2003 ◽  
Vol 29 (12) ◽  
pp. 2157-2161 ◽  
Author(s):  
Claudi S. M. Oude Nijhuis ◽  
Edo Vellenga ◽  
Simon M. G. J. Daenen ◽  
Winette T. A. van der Graaf ◽  
Jourik A. Gietema ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Diagnostic Marker ◽  
Binding Protein ◽  
Protein A ◽  
Lipopolysaccharide Binding Protein ◽  
Gram Negative ◽  
Gram Negative Bacteremia ◽  
Lipopolysaccharide Binding

Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood

2013 ◽  
Vol 28 (7) ◽  
pp. 1091-1097 ◽  
Author(s):  
Evanthia A. Tsalkidou ◽  
Emmanouel Roilides ◽  
Stefanos Gardikis ◽  
Gregory Trypsianis ◽  
Alexandros Kortsaris ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Binding Protein ◽  
Protein A ◽  
Lipopolysaccharide Binding Protein ◽  
Febrile Urinary Tract Infection ◽  
Potential Marker ◽  
Lipopolysaccharide Binding

scholarly journals Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 289
Author(s):  
Amelia Marti ◽  
Isabel Martínez ◽  
Ana Ojeda-Rodríguez ◽  
María Cristina Azcona-Sanjulian
Keyword(s):  
Metabolic Syndrome ◽  
Children And Adolescents ◽  
Lifestyle Intervention ◽  
Abdominal Obesity ◽  
Plasma Levels ◽  
Intervention Program ◽  
Binding Protein ◽  
Controlled Trial ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

Background: Elevated circulating plasma levels of both lipopolysaccharide-binding protein (LBP) and chemerin are reported in patients with obesity, but few studies are available on lifestyle intervention programs. We investigated the association of both LBP and chemerin plasma levels with metabolic syndrome (MetS) outcomes in a lifestyle intervention in children and adolescents with abdominal obesity Methods: Twenty-nine patients enrolled in a randomized controlled trial were selected. The lifestyle intervention with a 2-month intensive phase and a subsequent 10-month follow-up consisted of a moderate calorie-restricted diet, recommendations to increase physical activity levels, and nutritional education. Results: Weight loss was accompanied by a significant reduction in MetS prevalence (−43%; p = 0.009). Chemerin (p = 0.029) and LBP (p = 0.033) plasma levels were significantly reduced at 2 months and 12 months, respectively. At the end of intervention, MetS components were associated with both LBP (p = 0.017) and chemerin (p < 0.001) plasma levels. Conclusions: We describe for the first time a reduction in both LBP and chemerin plasma levels and its association with MetS risk factors after a lifestyle intervention program in children and adolescents with abdominal obesity. Therefore, LBP and chemerin plasma levels could be used as biomarkers for the progression of cardiovascular risk in pediatric populations.

scholarly journals Microbiome-Metabolomics Reveals Prebiotic Benefits of Fucoidan Supplementation in Mice

2021 ◽  
Vol 9 (5) ◽  
pp. 505
Author(s):  
Jingyi Yuan ◽  
Song Qin ◽  
Wenjun Li ◽  
Yubing Zhang ◽  
Yuting Wang ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Triglyceride Level ◽  
Lactobacillus Reuteri ◽  
Binding Protein ◽  
Serum Triglyceride ◽  
Serum Triglyceride Level ◽  
Lipopolysaccharide Binding Protein ◽  
Lactobacillus Gasseri ◽  
Lactobacillus Animalis ◽  
Lipopolysaccharide Binding

Fucoidan is a kind of polysaccharide with antitumor and antioxidant properties, which is mainly isolated from brown algae. Although there are many reports about the prebiotic effects of polysaccharides on hosts, there are few reports about the effects of fucoidan on blood biochemical indexes, intestinal microbiome, and metabolic function on healthy hosts. We applied 16S rRNA gene amplicon sequencing and LC-MS/MS metabolomics to evaluate the changes in the gut microbiome and metabolite profiles of fucoidan treatment in mice over 10 weeks. Fucoidan treatment modulated lipid metabolism, including significantly decreasing serum triglyceride level in healthy mice. Fucoidan also significantly inhibited serum lipopolysaccharide-binding protein (LBP) concentration, a biomarker of endotoxemia. Correlation analysis further showed that Lactobacillus animalis populations that were enriched by fucoidan demonstrated significantly negative correlations with serum triglyceride level. The abundance of Lactobacillus gasseri and Lactobacillus reuteri, increased by fucoidan supplementation, demonstrated significantly negative correlation with lipopolysaccharide-binding protein levels. Lactobacillus gasseri also demonstrated significantly positive correlations with three tryptophan-related metabolites, including indoleacrylic acid, 3-indoleacrylic acid, and 5-hydroxytryptamine, which were all increased by fucoidan administration. Combined with the previous evidence, the results indicate that fucoidan exerts prebiotic effects, such as lipid metabolism suppression and metabolic endotoxemia suppression, by modulating the abundance of gut microbiota, such as Lactobacillus animalis, Lactobacillus gasseri, and Lactobacillus reuteri, as well as microbiota-dependent metabolites, such as tryptophan-related metabolites.

Sign in / Sign up

Export Citation Format

Share Document